Hand holding the newspaper resting on a table with a cup of coffee

Newsroom

Taxonomy Icon
  • November 23, 2019
  • Source: The Onco'Zine Brief
In this edition of The Onco’Zine Brief, Peter Hofland talks with Catherine Ivy about how after losing her husband Ben to glioblastoma she became a tireless advocate for brain cancer patients.
Taxonomy Icon
  • November 21, 2019
  • Source: Onco'Zine - The International Oncology Network
Taxonomy Icon
  • November 21, 2019
The Ivy Brain Tumor Center at the Barrow Neurological Institute, today announced a strategic collaboration with SonALASense to develop and test a new, non-invasive drug-device combination, sonodynamic therapy (SDT), for recurrent glioblastoma through a Phase 0/2 clinical trial.
Taxonomy Icon
  • October 30, 2019
  • Source: Your Mark On The World
Catherine Ivy sat down with Devin Thorpe's Your Mark On The World to discuss her personal fight with glioblastoma and how she hopes to shake up the research process with her investment in the Ivy Center's Phase 0 clinical trials.
Taxonomy Icon
  • September 24, 2019
The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma, Inc., to investigate the FGFR1-3 tyrosine kinase inhibitor, infigratinib, for the treatment of glioblastoma (GBM).
Taxonomy Icon
  • September 12, 2019
  • Source: Authority Magazine
Catherine Ivy was recently interviewed for Authority Magazine's latest "Social Impact Heroes" series where she opened up about her 14-year journey to accelerate drug discovery for brain tumor patients, a recent success story from the Ivy Center's Phase 0 clinical trials program, and what our community, society and politicians can do to help address the unmet needs of patients battling aggressive brain tumors.
Taxonomy Icon
  • August 26, 2019
The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a collaborative partnership to test Salarius’ therapeutic candidate, Seclidemstat, for the treatment of glioblastoma.
Taxonomy Icon
  • August 25, 2019
  • Source: 3TV | Good Morning Arizona
Ivy Brain Tumor Center, deputy director, Dr. Shwetal Mehta, was interviewed by Good Morning Arizona to discuss the Ivy Center's Phase 0 clinical trials program and the challenges of fighting a disease like glioblastoma.
Taxonomy Icon
  • July 26, 2019
  • Source: TrialSiteNews
The Ivy Brain Tumor Center at the Barrow Neurological Institute recently completed a Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali) for the treatment of recurrent glioblastoma. The Ivy recently received $50 million to combat brain cancer. This new drug cocktail represents one of the potential weapons in humankind’s war against this killer disease.
Taxonomy Icon
  • July 26, 2019
Barrow Neurological Foundation led a fundraising effort that raised more than $539,000 for brain cancer research at the Ivy Brain Tumor Center on the first ever Glioblastoma Awareness Day, July 17, 2019.